Discontinuing Buprenorphine

Slides:



Advertisements
Similar presentations
13 Principles of Effective Addictions Treatment
Advertisements

INDIVIDUAL VERSUS TECHNOLOGY Research, treatment and policy - ethical dilemmas Gabrielle Welle-Strand - Researcher, MD, Senior Adviser Pompidou Group –
Hepatitis web study Hepatitis web study Simeprevir in Genotype 1 (Viral Relapsers) PROMISE Trial Phase 3 Treatment Experienced Forns X, et al. Gastroenterology.
Dosing and patient management requirements during induction, stabilization, and detoxification with buprenorphine Matthew A. Torrington MD Clinical Research.
Pharmacologic Treatments. 2 Cognitive Behavioural Therapy (CBT) Psychosocial Interventions.
1 CHANGES IN SEXUAL INTEREST AND PERFORMANCE FOLLOWING OPIATE DETOXIFICATION AND ORAL NTX TREATMENT A PROSPECTIVE STUDY Emmanuel Koukidis, MSc, BTEC in.
Addiction A-Pharmacological approaches to treating drug dependence B-Clinical use of drugs in substance dependence.
Clinical Use of Buprenorphine Finding The Right Dose Paul P. Casadonte MD California Society of Addiction Medicine 2002.
Module 4: Interaction of. Objectives To be aware of the possible reasons why dual diagnosis occurs To be aware of the specific effects of substances on.
Sublingual Buprenorphine and Pain
University of Utah Department of Human Genetics The New Science of Addiction Louisa A. Stark, Ph.D. Director.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Copyright Alcohol Medical Scholars Program 1 Opioid Agonist Treatment: “Trading one substance for another?” Joseph Sakai, M.D.
JANUARY 2013 SUBSTANCE ABUSE TREATMENTBASICS. WHY DO PEOPLE USE DRUGS AND ALCOHOL? People use substances such as alcohol and other drugs because they.
Developments in Community - Based Drug Treatments Lesley Peters
Treating Addiction Heroin Nicotine. Treating Heroin addiction with Methadone What is Methadone? Methadone is a synthetic opiate which replaces heroin.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Recovery Centers of King County Buprenorphine Treatment Program AAP Providers Conference, April 19, 2013, Lynnwood, WA Patricia C. Knox, Ph.D.
Colin Brewer, Research Director, The Stapleford Centre, London UK. Manos Koukides, Counsellor, Life Care NGO, Greece. Matina Lagoudaki, Psychologist, Life.
Drug treatments for heroin dependence heroin dependence.
Diagnosis And Treatment Of Prescription Opioid Dependence Steven W. Clay, D.O. Associate Professor, Department of Family Medicine Ohio University College.
Substance Abuse Treatment. PROFILE OF A DRUG ABUSER  MOST PEOPLE IN TREATMENT ARE BETWEEN YEARS OF AGE  MANY DRUG ABUSERS SUFFER FROM MENTAL HEALTH.
Behavioral Interventions for HIV Risk Reduction and HIV Prevention: An International Perspective Marek C. Chawarski Yale University School of Medicine.
Suboxone as an Adjunctive Medication, Not Maintenance Dennis M. Donovan, Ph.D. UW Alcohol & Drug Abuse Institute Patricia C. Knox, Ph.D. Recovery Centers.
Chapter 13 Tobacco Lesson 3 Tobacco Addiction Next >> Click for:
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
Relapse Back to Smoking: The Core Role of the Tobacco Withdrawal Syndrome WITH THOMAS PIASECKI MICHAEL FIORE.
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
OPIOID SUBSTITUTION THERAPY
1 First aid courses and use of Naloxone by drug users Experience gained with a model project by Fixpunkt e. V., Berlin Germany Prevention of emergencies.
Medications for Pain: What You Need to Know for Treatment in Workers’ Compensation Suzanne Novak, MD, PhD 5/17/07.
FIVE MINUTES TO MAKE A DIFFERENCE Presentation by: Mark Barnes.
Medical issues about Methadone : What the counselor needs to know
Opiate Receptor Pharmacology
BUPRENORPHINE TREATMENT Curriculum Infusion Package (CIP) Based on the Work of Dr. Thomas Freese of the Pacific Southwest ATTC Drug Addiction Treatment.
Module 1 General introduction to substitution treatment.
Opioids Unless otherwise indicated, the answers are from DSM-IV-TR and APA Practice Guidelines, AJP Supplement, August, As of 3Aug06.
 Methadone is prescribed to relieve moderate to severe pain that has not been relieved by non-narcotic pain relievers.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
BUPRENORPHINE TREATMENT: A Training For Addiction Professionals BUPRENORPHINE TREATMENT: A Training For Multidisciplinary Addiction Professionals Module.
Rational Prescribing & Prescription Writing Once a patient with a clinical problem has been evaluated and a diagnosis has been reached, the practitioner.
Schizophrenia Pathogenesis is unknown. Onset of schizophrenia is in the late teens - early ‘20s. Genetic predisposition -- Familial incidence. Multiple.
DRUG ADDICTION TREATMENTS
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
1 Medication Development for Treatment of Drug Dependence Donald R. Wesson, MD Consultant, CNS Medications Development Chairman, ASAM Medications Development.
Benjamin J. Pariser, DO RASE Physician.  This presentation will review the option of Medication Assisted Treatment as part of a comprehensive recovery.
Addiction vs. Physical Dependence Katie Ulrich Clinical Psychologist.
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
Prepared by Dr. Ramin Safakish, MD, FRCPC – March 2016.
COMPARATIVE STUDY OF ORMELOXIFENE AND MEDROXYPROGESTERENE ACETATE IN ABNORMAL UTERINE BLEEDING.
Gregory S. Brigham, Ph.D., CEO
Clinical Opiate Withdrawal – Symptom Management Protocol
big blue adderall pill u27
Medication-Assisted Therapy at Coleman Profession Services
Types of Intervention.
WHY A FOCUS ON ADDICTIVE BEHAVIORS?
Drugs.
Opioids – A Pharmaceutical Perspective on Prescription Drugs
Other drugs used in the treatment of bipolar disorder
Tremor Domina Petric, MD.
Choosing to Live Tobacco Free
DIVISION shortcuts Ready for some magic?.
Algorithm based on the 2015 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) recommendations for the management of polymyalgia.
Describe and Evaluate Biological Treatments for Schizophrenia
Medication Assisted Treatment of Opioid Use Disorder
Receptor Sends Pain Signal to the Brain
Patient disposition. *Patients who switched multiple times were not included in this analysis; **for patients switching treatment regimens, discontinuations.
How Should We Select and Define Trial Estimands
Presentation transcript:

Discontinuing Buprenorphine Donald R. Wesson, MD

Words to use and not use Use “Discontinuation” or “Tapering” Don’t use “detoxification” because it implies that buprenorphine is toxic

Have a Well-defined Reason for Discontinuation Voluntary No longer needed to prevent relapse to heroin use (you won’t know until you try) Involuntary Buprenorphine not effective (e.g., heroin use continuing at level similar to pre-buprenorphine dosing) Intolerable office behavior (e.g., drug dealing to other patients)

Discontinuation of Psychosocial and buprenorphine Treatment Generally a bad idea to discontinue both at once Discontinue buprenorphine treatment then psychosocial treatment

Rate of Taper Taper buprenorphine slowly over weeks to months Be prepared to discontinue taper and increase buprenorphine dose if relapse to heroin appears imminent or if heroin use occurs

Dosing Strategy If patient starts having inter-dose opiate withdrawal symptoms, divide dosage to twice or three times daily